Journal
CLINICAL NUTRITION
Volume 40, Issue 7, Pages 4538-4550Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.clnu.2021.05.025
Keywords
Eicosapentaenoic acid; Docosahexaenoic acid; Metabolic syndrome; Meta-analysis; Randomized controlled trial
Categories
Funding
- Key Scientific Research Projects in Shandong Province China [2017YYSP007]
- National Natural Science Foundation of China [81773433]
Ask authors/readers for more resources
The study found that EPA and DHA have different effects on reducing metabolic syndrome risk factors. EPA is effective in lowering total cholesterol, triglycerides, and low-density lipoprotein cholesterol levels, while DHA can increase total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels, as well as insulin levels in certain subgroups.
Background & aims: Previous randomized controlled trials (RCTs) have compared the effects of pure preparations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in reducing metabolic syndrome (MetS) risk factors, but the results were inconsistent. The present study aimed to clarify whether EPA and DHA have differential effects on MetS features in humans. Methods: A systematic literature search was conducted in CNKI, PubMed, Embase and Scopus updated to February 2021. The mean changes in the characteristics of MetS were calculated as weighted mean differences by using a random-effects model. Thirty-three RCTs were included. Results: The results showed that both EPA and DHA were effective at lowering serum triglycerides (TG) levels. EPA supplementation decreased the serum levels of total cholesterol (TC) (WMD = -0.24 mmol/L; 95% CI, -0.43, -0.05 mmol/L), TG (WMD = -0.77 mmol/L; 95% CI, -1.54, -0.00 mmol/L) and low density lipoprotein-cholesterol (LDL-C) (WMD = -0.13 mmol/L; 95% CI, -0.25, -0.01 mmol/L), while DHA increased the serum levels of TC (WMD = 0.14 mmol/L; 95% CI, 0.03, 0.25 mmol/L), LDL-C (WMD = 0.26 mmol/L; 95% CI, 0.15, 0.38 mmol/L) and high density lipoprotein-cholesterol (HDL-C) (WMD = 0.07 mmol/L; 95% CI, 0.04, 0.09 mmol/L). Moreover, DHA increased the serum levels of insulin compared with EPA, especially in subgroups whose mean age was <60 years (0.43 mU/L; 95% CI: 0.04, 0.81 mU/L) and duration of DHA supplementation < 3 months (0.39 mU/L; 95% CI: 0.01, 0.77 mU/L). Conclusions: The present meta-analysis provides evidence that EPA and DHA have different effects on risk factors of MetS. (c) 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available